Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb’s Plavix “less effective”

Bristol-Myers Squibb’s Plavix “less effective”

23rd December 2008

Bristol-Myers Squibb’s Plavix has been found to be less effective for young heart attack survivors with a common genetic variation.

French researchers found users with the gene were more likely to die, have a serious heart problem or were at increased risk of blood clots while taking the blood thinning drug, in comparison to those who had stents implanted.

However, the scientists cautioned it was too soon to start genetically testing patients for the variation without further study.

Gilles Montalescot of Pitie-Salpetriere Hospital in Paris and colleagues wrote in the journal Lancet: “These findings need to be independently replicated … before being extrapolated to older patients or those of non-European ancestry.”

Researchers examined the CYP2C19 gene, which plays a “key role” in determining how individuals metabolise commonly prescribed drugs and appeared in over a quarter of the subjects in the tests.

Involving 259 men and women aged below 45 years old – who had survived a heart attack and were on clopidogrel for over 12 months – the study ran from 1996 to this year.

Last week, Bristol-Myers Squibb’s board of directors announced its quarterly dividend as $0.31 (0.21 pounds) per share on the $.10 par value common stock of the organisation.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.